These findings suggest that high SOCS2 expression is correlated with a better prognosis for HCC patients and that by promoting K48‐linked polyubiquitination degradation of SLC7A11, SOCS2 can serve as a potential target for HCC treatment [30]. This evidence concerns the gene SLC7A11 and hepatocellular carcinoma.